Skip to main content
. Author manuscript; available in PMC: 2021 Aug 4.
Published in final edited form as: Clin Cancer Res. 2021 May 20;27(15):4311–4324. doi: 10.1158/1078-0432.CCR-21-0136

Figure 3. Sex-based differences in TCR repertoire, tumor antigenicity and alterations in antigen presentation machinery.

Figure 3

Figure reports TCR diversity score (panel A), number of expanded ubiquitous TCRs (panel B), clonal, subclonal and total number of neoantigens (panel C) calculated in tumors of men and women. Panel D and panel E report respectively, number of patients with tumors harboring or not HLA type I Loss of Heterozygosity (LOH), or disruptive events in other genes of antigens presentation machinery